FUJIY News and Press, FUJIFILM Holdings Corp ADR 2 Ord From 12/29/20

Canon has seen its business consistently deteriorate since its peak in 2007. With the pandemic highlighting its fundamental weaknesses further, the shares are a sell. With office equipment demand falling and cameras on a continued decline, the core earnings drivers will be unable to m...

FUJIFILM ([[FUJIY]] +0.1%) Medical Systems U.S.A., has entered the surgical and fluoroscopy markets with two new systems: the Persona C Surgical C-Arm and Persona RF PREMIUM System.These systems will provide digital x-ray imaging studies and fluoroscopy exams, allowing physicians to enhance w...

FUJIFILM Medical Systems ([[FUJIY]] +0.8%) and Volpara Solutions expands partnership to provide mammography facilities and clinicians with breast imaging solutions designed to improve image quality, streamline workflow and accurately assess a patient's breast density."Consistent ...

On Sep. 22, Fujifilm (OTC: FUJIY) reported that a phase 3 clinical trial of its influenza pill, Avigan, showed the treatment's ability to reduce the recovery time of patients with mild cases of COVID-19. These results gave Fujifilm's stock a small bump of more than 4%, but the marke...

Will an anti- COVID-19 vaccine be effective? Much has been written about the potential of multiple vaccines to ultimately prevent COVID-19, the condition caused by the SARS-CoV-2 coronavirus. However, despite Operation Warp Speed and the immense hyperbole surrounding vaccine candidates in...

We cannot afford to sell our Canon ( CAJ ) position at a loss. Our fearless forecast is that CAJ can bounce back next year after this COVID-19 headwind dissipates. We should average down because the -28.35% 1-year price return of CAJ is something we (true believers of Canon) comprehend and for...

The value of proper clinical trials is that they give results that give confidence in the efficacy (or otherwise) of drugs. The UK has a complex major trial (RECOVERY) for testing drugs for treating COVID-19. Recent results from this trial were pivotal in the FDA deciding that hydroxychloro...

Galidesivir, not berotralstat, will be the BCRX catalyst Oral berotralstat is soon likely to gain approval in three regions - Japan, the U.S., and Europe - for the treatment of HAE. In Japan, a new drug application for berotralstat is currently being reviewed by the Pharmaceuticals and Med...

I’m writing this after market close and the S&P 500 ( SPY ) and the Dow (DJI) are up 7%-8% again. It is quite the bear rally from the lows in March. I’m watching Twitter, talking to other investors, listening to CNBC, lots of investment podcasts, and of course, reading the fi...

Drivers of the multi-year underperformance US Healthcare is the 2nd largest equity sector, with a 14% index weight , and has been a perennial underperformer the last five years (see chart), and lagged by 10 points last year alone. This was even as the sector has continued to post robust g...